Determining the Reimbursed Price for Pharmaceuticals in Germany: An Overview
In April 2024, I wrote a guest post for Market Access Today. Introduction Entering the dynamic realm of pharmaceutical pricing in Germany,
Category: Pricing
Confidentiality vs. Transparency: Germany’s Drug Price Dilemma Unpacked
Are confidential drug prices coming to Germany? Until now, the reimbursed prices of drugs are in the public domain (Lauer Taxe), but
Determining the Reimbursed Price for Pharmaceuticals in Germany
Introduction Entering the dynamic realm of pharmaceutical pricing in Germany, we find ourselves immersed in a landscape defined by regulations, negotiations, price
Lung cancer drug taken off German market because of no additional benefit rating
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
German Health minister presents new draft of act to stabilise SHI fund finances
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version